
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is expected to see a recovery in the second half of 2026, driven by an increase in utilization and a slight uptick in LDD placements. With an expected growth in low-single digit for LAL units, the overall growth should improve sequentially throughout the year. The company showed healthy gross margins in the fourth quarter of 2025, beating expectations due to a favorable product mix. However, investors should be aware of the risks, including limited adoption, potential competition, and the possibility of a dilutive financing round.
Bears say
RxSight is facing a number of risks that could limit adoption of its technology, such as the need for additional capital equipment, potential competition in the IOL market, and possible dilutive financing. The company also saw a decline in LDD placements and a slower-than-expected growth in LAL sales, which could indicate challenges in commercial execution. Additionally, the company's focus on driving LAL volumes through engagement initiatives may not be enough to offset flat to down LDD placements, which could lead to continued revenue declines. Overall, the company's uncertainty and slower-than-expected growth potential led to a negative outlook.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares